I came across the following on the dailystrength.org website discussion of Ila Singh's patent application. As I haven't seen the original patent application I can't vouch for its accuracy but I don't believe this has been discussed yet?
http://www.dailystrength.org/c/Chronic_Fatigue_Syndrome/forum/10982461-cfsme-cfidsxmrv-there
METICULOUSLY ADDRESSING THE CONTAMINATION ISSUE
[0094] It was important to ensure that the assay specifically amplified XMRV sequences and not other murine or human endogenous retroviral sequences.
In research laboratories, human tissue blocks are often sectioned on the same microtomes used for murine tissues, and contamination with murine samples can result in non-specific amplification of exogenous or endogenous murine retroviruses that are present in multiple copies in the mouse genome and have high sequence similarity to XMRV (Figure 2A).
Systematic scanning of the XMRV genome identified a region of the putative gag gene that was 100% conserved between all published XMRV clones (total of 3), and yet shared at most 80% similarity with the most closely related 11 murine retroviral sequences (Figure 2A). Primers and probes in this region allowed efficient detection of XMRV without interference from related murine retroviral sequences.
ENSURING SPECIFICITY TO RULE OUT DETECTION OF MURINE ENDOGENOUS RETROVIRUSES
To test for amplification of murine ERVs, genomic DNA of a
C57BL/6 mouse was used as template. To rule out amplification of human ERVs or other human sequences related to XMRV, commercially available human placental DNA was used as template. Also mouse DNA was mixed with human placental DNA at different ratios. No amplification product was observed in any of the reactions, showing that the qPCR assay was highly specific for XMRV.